These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8454379)

  • 21. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial.
    Dössegger L; Aldor E; Baird MG; Braun S; Cleland JG; Donaldson R; Jansen LJ; Joy MD; Marin-Neto JA; Nogueira E
    Eur Heart J; 1993 Jul; 14 Suppl C():18-23. PubMed ID: 8365423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
    Hansen MS; Stanton EB; Gawad Y; Packer M; Pitt B; Swedberg K; Rouleau JL;
    Am J Cardiol; 2002 Nov; 90(9):969-73. PubMed ID: 12398964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study.
    Cowley AJ; Wynne RD; Hampton JR
    Eur J Clin Pharmacol; 1987; 33(2):203-4. PubMed ID: 2891533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure.
    Elborn JS; Riley M; Stanford CF; Nicholls DP
    Br J Clin Pharmacol; 1990 May; 29(5):519-24. PubMed ID: 2112405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
    Starling MR
    Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
    Schneeweiss A; Marmor A; Wynne RD
    Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
    Schneeweiss A; Wynne RD; Marmor A
    Crit Care Med; 1989 Sep; 17(9):879-81. PubMed ID: 2766758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.
    Ng HW; Walley TJ; Tsao Y; Breckenridge AM
    Eur J Clin Pharmacol; 1994; 46(4):361-5. PubMed ID: 7957523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of flosequinan and nifedipine on glucose tolerance in healthy volunteers.
    Lewis H; Kendall M; Bratty JR
    J Clin Pharm Ther; 1988 Aug; 13(4):269-72. PubMed ID: 3235476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
    Markus H; Cowley AJ
    Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition.
    Elkayam U; Johnson JV; Shotan A; Bokhari S; Solodky A; Canetti M; Wani OR; Karaalp IS
    Circulation; 1999 May; 99(20):2652-7. PubMed ID: 10338458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
    Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
    Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus.
    Lewis HM; Kendall MJ; Wright AD; Bratty JR; Maxwell S
    J Clin Pharm Ther; 1991 Jun; 16(3):161-6. PubMed ID: 1869595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exercise tolerance in patients with heart failure--how should it be measured?
    Cowley AJ; Fullwood L; Stainer K; Hampton JR
    Eur Heart J; 1991 Jan; 12(1):50-4. PubMed ID: 2009893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.
    Lewis HM; Kendall MJ; Smith SR; Bratty JR
    Br J Clin Pharmacol; 1989 May; 27(5):547-52. PubMed ID: 2757879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.